AndroBioSys Inc.
This article was originally published in Start Up
Executive Summary
AndroBioSys is pursuing a dual strategy for treating prostate disease: it's running a contract research business while it builds a therapeutic pipeline. One of the company's programs is based on the discovery of a novel enzyme that converts testosterone to dihydrotestosterone, which is the most potent activator of the androgen receptor. Another program focuses on a target on prostate cancer stem cells that makes them resistant to chemotherapy. The company is working on developing an assay to detect circulating prostate cancer stem cells, which could guide physicians in determining how aggressively to treat the patient. The next step would be to develop a therapy capable of eliminating such cells.